Is GE Healthcare Technologies, Inc. overvalued or undervalued?

As of 17 October 2025, the valuation grade for GE Healthcare Technologies, Inc. has moved from attractive to very attractive, indicating a strong improvement in its valuation outlook. The company appears to be undervalued, supported by a P/E ratio of 14, a PEG ratio of 0.39, and an EV to EBITDA of 11.16. In comparison, peers such as Edwards Lifesciences Corp. exhibit a significantly higher P/E of 31.17 and EV to EBITDA of 26.51, while Agilent Technologies, Inc. has a P/E of 27.42, further highlighting GE Healthcare's relative value.
Although specific return data is not available, the absence of negative returns relative to the S&P 500 would suggest that the stock is performing well in the current market context. Overall, the combination of favorable valuation ratios and the peer comparison reinforces the conclusion that GE Healthcare Technologies, Inc. is undervalued.